Brokerages Expect Jazz Pharmaceuticals PLC (JAZZ) to Post $2.91 EPS

Brokerages expect Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to announce $2.91 earnings per share for the current fiscal quarter, Zacks reports. Eight analysts have provided estimates for Jazz Pharmaceuticals’ earnings, with estimates ranging from $2.83 to $3.04. Jazz Pharmaceuticals posted earnings of $2.95 per share in the same quarter last year, which would suggest a negative year over year growth rate of 1.4%. The firm is scheduled to announce its next earnings results on Tuesday, February 26th.

According to Zacks, analysts expect that Jazz Pharmaceuticals will report full year earnings of $12.98 per share for the current year, with EPS estimates ranging from $12.89 to $13.10. For the next fiscal year, analysts anticipate that the business will post earnings of $13.82 per share, with EPS estimates ranging from $13.05 to $14.78. Zacks’ EPS averages are a mean average based on a survey of research firms that that provide coverage for Jazz Pharmaceuticals.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.32 by $0.26. The business had revenue of $469.37 million for the quarter, compared to analysts’ expectations of $482.64 million. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The business’s revenue was up 14.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.22 earnings per share.

A number of equities research analysts have weighed in on JAZZ shares. Cowen set a $200.00 price objective on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, November 7th. Wells Fargo & Co restated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Wednesday, November 7th. Royal Bank of Canada set a $184.00 target price on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, November 7th. Piper Jaffray Companies set a $208.00 target price on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, November 7th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $201.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, November 6th. Six investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Jazz Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $189.76.

JAZZ traded down $2.33 during midday trading on Friday, reaching $141.17. The company’s stock had a trading volume of 975,543 shares, compared to its average volume of 729,139. The stock has a market cap of $8.66 billion, a PE ratio of 14.77, a price-to-earnings-growth ratio of 0.86 and a beta of 0.94. The company has a debt-to-equity ratio of 0.52, a quick ratio of 4.16 and a current ratio of 4.29. Jazz Pharmaceuticals has a 1 year low of $130.15 and a 1 year high of $184.00.

In related news, Director Seamus Mulligan acquired 50,000 shares of the stock in a transaction that occurred on Thursday, November 15th. The shares were bought at an average price of $144.56 per share, for a total transaction of $7,228,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,300 shares of the stock in a transaction that occurred on Friday, September 21st. The shares were sold at an average price of $164.36, for a total transaction of $213,668.00. Following the transaction, the chief executive officer now owns 281,215 shares in the company, valued at approximately $46,220,497.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 6,600 shares of company stock worth $1,063,472. Insiders own 3.90% of the company’s stock.

A number of institutional investors have recently modified their holdings of JAZZ. BlackRock Inc. lifted its position in Jazz Pharmaceuticals by 64.0% during the second quarter. BlackRock Inc. now owns 4,372,080 shares of the specialty pharmaceutical company’s stock valued at $753,311,000 after purchasing an additional 1,706,417 shares during the period. FMR LLC lifted its position in Jazz Pharmaceuticals by 12.1% during the second quarter. FMR LLC now owns 6,634,958 shares of the specialty pharmaceutical company’s stock valued at $1,143,203,000 after purchasing an additional 715,595 shares during the period. AGF Investments Inc. bought a new position in Jazz Pharmaceuticals during the second quarter valued at approximately $78,345,000. Voya Investment Management LLC bought a new position in Jazz Pharmaceuticals during the second quarter valued at approximately $70,215,000. Finally, Fiera Capital Corp bought a new position in Jazz Pharmaceuticals during the second quarter valued at approximately $54,662,000. Institutional investors own 91.53% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Recommended Story: Balanced Fund

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply